Debunking Biopharmaceutical Patent Myths: An Evidence-Based Analysis
Debunking Biopharmaceutical Patent Myths: An Evidence-Based Analysis
IPO Comments to CNIPA on Draft Amendments to the Measures for the Administration of Patent Priority Examination
IPO Comments to CNIPA on Draft Amendments to the Measures [...]
You Can’t (Always) Claim What You Didn’t Describe: U.S. and European Perspectives on Chemical Patents
You Can’t (Always) Claim What You Didn’t Describe: U.S. and [...]
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin Pharma, Inc., 24-889
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin [...]
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney Privilege
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney [...]
IPO Post-Hearing Statement to Special 301 Subcommittee
IPO Post-Hearing Statement to Special 301 SubcommitteeReadability analysis:
IPO Comments to India Department for Promotion of Industry and Internal Trade (DPIIT) on its “Concept Note: Proposed Amendment to the Designs Act, 2000″
IPO Comments to India Department for Promotion of Industry and [...]
IPO Comments to the China Standing Committee of the National People’s Congress (NPC) Regarding Draft Amendment to the Trademark Law of the People’s Republic of China
IPO Comments to the China Standing Committee of the National [...]
Resolution on Cross‑Border Patent Practitioner Privilege
RESOLVED, IPO supports the application of a privilege, analogous to [...]
IPO Comments to the Supreme People’s Court of the People’s Republic of China Regarding Draft Interpretation on Several Issues Concerning the Application of Law in the Trial of Patent Infringement Disputes
IPO Comments to the Supreme People’s Court of the People’s [...]